Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease in Europe through percutaneous cardiovascular interventions.
Our mission is to improve the quality of life of the population by reducing the impact of cardiac rhythm disturbances and reduce sudden cardiac death.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Anna F Dominiczak,
The session on a stratified approach to resistant hypertension brought together four excellent presentations, including Professor Roland Schmieder’s outstanding account of the diagnostic and therapeutic aspects of resistant hypertension in line with the new 2013 ESH/ESC Guidelines. This was followed by a clinical talk on management of resistant hypertension by Dr Adrian Brady, which included interesting case histories. The presentation on the role of metabolomics and genomics in delivering early interventions described new technological and bioinformatic advances in the area of polyomics, which although not yet ready for clinical practice, have been shown to discover new pathways and new mechanisms in cardiovascular disease.Last but not least, Professor Michel Azizi described exciting new inhibitors of the mineralocorticoid system. He demonstrated the mode of action and selectivity of the aldosterone synthase inhibitors (ASI) and showed very interesting data on non-steroidal antagonists of the mineralocorticoid receptor. The comparison between these compounds revealed that the latter group of compounds might be both superior and highly desirable in essential hypertension and perhaps also in early and potentially reversible primary aldosteronism.
Stratified approach to resistant hypertension
© 2017 European Society of Cardiology. All rights reserved